These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26706277)

  • 1. Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains.
    Kim JH; Liepkalns J; Reber AJ; Lu X; Music N; Jacob J; Sambhara S
    Vaccine; 2016 Jan; 34(4):495-502. PubMed ID: 26706277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
    Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.
    Ikeda K; Ainai A; Hasegawa H
    Vaccine; 2015 Nov; 33(45):6066-9. PubMed ID: 26432916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.
    Xie H; Li X; Gao J; Lin Z; Jing X; Plant E; Zoueva O; Eichelberger MC; Ye Z
    Clin Infect Dis; 2011 Dec; 53(12):1179-87. PubMed ID: 21976461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory vaccination of mice against influenza virus: dissection of T- and B-cell priming functions.
    Coleclough C; Sealy R; Surman S; Marshall DR; Hurwitz JL
    Scand J Immunol; 2005 Jul; 62 Suppl 1():73-83. PubMed ID: 15953188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chitosan as an adjuvant for parenteral inactivated influenza vaccines].
    Gendon IuZ; Markushin SG; Krivtsov GG; Akopova II
    Vopr Virusol; 2008; 53(5):14-9. PubMed ID: 19069787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
    Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
    Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
    Wen F; Yu H; Yang FR; Huang M; Yang S; Zhou YJ; Li ZJ; Tong GZ
    Arch Virol; 2014 Nov; 159(11):2957-67. PubMed ID: 24957653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.
    Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S
    J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.